Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "CEP"

1785 News Found

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes
Clinical Trials | March 16, 2026

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes

This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin


Finerenone hits major goal in Phase III FIND-CKD trial
Clinical Trials | March 16, 2026

Finerenone hits major goal in Phase III FIND-CKD trial

There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk


Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
News | March 14, 2026

Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds

Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound


Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
Clinical Trials | March 14, 2026

Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug

The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days


Zydus receives USFDA approval for cevimeline hydrochloride capsules
Drug Approval | March 14, 2026

Zydus receives USFDA approval for cevimeline hydrochloride capsules

Cevimeline Hydrochloride Capsules 30mg are indicated for the symptomatic treatment of dry mouth (xerostomia) associated with Sjögren’s syndrome.


Single-use gloves misused across India, raising health risks
Healthcare | March 14, 2026

Single-use gloves misused across India, raising health risks

One task, one interaction, one pair, experts advocate


MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
Biotech | March 14, 2026

MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel

The protections extend through at least 2035, with the potential for further extensions


Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial
Clinical Trials | March 12, 2026

Vertex Pharmaceuticals’ new kidney drug shows dramatic results in Phase 3 trial

The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36